LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Authors:
- X. LeXLX. Le
- J. PatelJPJ. Patel
- E. ShumESE. Shum
- R.E. SanbornRSR.E. Sanborn
- C.S. BaikCBC.S. Baik
- C.A. ShuCSC.A. Shu
- C. KimCKC. Kim
- FidlerFIFidler
- R. HallRHR. Hall
- N. HannaNHN. Hanna
- N. MohindraNMN. Mohindra
- J.K. SabariJSJ.K. Sabari
- 20 October 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1313-S1314